These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Evaluation of the Binding Affinity of Anti-Viral Drugs against Main Protease of SARS-CoV-2 Through a Molecular Docking Study. Mondal M; Sarkar C; Jamaddar S; Khalipha ABR; Islam MT; Mahafzah A; Mubarak MS Infect Disord Drug Targets; 2021; 21(7):e160921188777. PubMed ID: 33292147 [TBL] [Abstract][Full Text] [Related]
4. Structure-based drug repurposing for targeting Nsp9 replicase and spike proteins of severe acute respiratory syndrome coronavirus 2. Chandel V; Sharma PP; Raj S; Choudhari R; Rathi B; Kumar D J Biomol Struct Dyn; 2022 Jan; 40(1):249-262. PubMed ID: 32838660 [TBL] [Abstract][Full Text] [Related]
5. Computational screening of dual inhibitors from FDA approved antiviral drugs on SARS-CoV-2 spike protein and the main protease using molecular docking approach. Sabarimurugan S; Purushothaman I; Swaminathan R; Dharmarajan A; Warrier S; Kothandan S Acta Virol; 2021; 65(2):160-172. PubMed ID: 34130467 [TBL] [Abstract][Full Text] [Related]
6. Molecular Docking and ADMET Prediction of Natural Compounds towards SARS Spike Glycoprotein-Human Angiotensin-Converting Enzyme 2 and SARS-CoV-2 Main Protease. Oso BJ; Olaoye IF; Omeike SO Arch Razi Inst; 2021; 76(3):453-459. PubMed ID: 34824739 [TBL] [Abstract][Full Text] [Related]
7. A Novel Therapeutic Peptide Blocks SARS-CoV-2 Spike Protein Binding with Host Cell ACE2 Receptor. Rajpoot S; Ohishi T; Kumar A; Pan Q; Banerjee S; Zhang KYJ; Baig MS Drugs R D; 2021 Sep; 21(3):273-283. PubMed ID: 34324175 [TBL] [Abstract][Full Text] [Related]
8. Lead Finding from Selected Flavonoids with Antiviral (SARS-CoV-2) Potentials Against COVID-19: An In-silico Evaluation. Gorla US; Rao K; Kulandaivelu US; Alavala RR; Panda SP Comb Chem High Throughput Screen; 2021; 24(6):879-890. PubMed ID: 32819226 [TBL] [Abstract][Full Text] [Related]
9. De novo design of novel protease inhibitor candidates in the treatment of SARS-CoV-2 using deep learning, docking, and molecular dynamic simulations. Arshia AH; Shadravan S; Solhjoo A; Sakhteman A; Sami A Comput Biol Med; 2021 Dec; 139():104967. PubMed ID: 34739968 [TBL] [Abstract][Full Text] [Related]
10. In silico drug discovery of major metabolites from spices as SARS-CoV-2 main protease inhibitors. Ibrahim MAA; Abdelrahman AHM; Hussien TA; Badr EAA; Mohamed TA; El-Seedi HR; Pare PW; Efferth T; Hegazy MF Comput Biol Med; 2020 Nov; 126():104046. PubMed ID: 33065388 [TBL] [Abstract][Full Text] [Related]
11. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing. Kumar Y; Singh H; Patel CN J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274 [TBL] [Abstract][Full Text] [Related]
12. Stilbene-based natural compounds as promising drug candidates against COVID-19. Wahedi HM; Ahmad S; Abbasi SW J Biomol Struct Dyn; 2021 Jun; 39(9):3225-3234. PubMed ID: 32345140 [TBL] [Abstract][Full Text] [Related]
13. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening. Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740 [TBL] [Abstract][Full Text] [Related]
17. Cyanobacterial metabolites as promising drug leads against the M Naidoo D; Roy A; Kar P; Mutanda T; Anandraj A J Biomol Struct Dyn; 2021 Oct; 39(16):6218-6230. PubMed ID: 32691680 [TBL] [Abstract][Full Text] [Related]
18. Silybin B and Cianidanol Inhibit M Srivastava R; Tripathi S; Unni S; Hussain A; Haque S; Dasgupta N; Singh V; Mishra BN Curr Pharm Des; 2021; 27(32):3476-3489. PubMed ID: 33302853 [TBL] [Abstract][Full Text] [Related]
19. Anthocyanin derivatives as potent inhibitors of SARS-CoV-2 main protease: An in-silico perspective of therapeutic targets against COVID-19 pandemic. Fakhar Z; Faramarzi B; Pacifico S; Faramarzi S J Biomol Struct Dyn; 2021 Oct; 39(16):6171-6183. PubMed ID: 32741312 [TBL] [Abstract][Full Text] [Related]
20. Field-Template, QSAR, Ensemble Molecular Docking, and 3D-RISM Solvation Studies Expose Potential of FDA-Approved Marine Drugs as SARS-CoVID-2 Main Protease Inhibitors. Kalhotra P; Chittepu VCSR; Osorio-Revilla G; Gallardo-Velazquez T Molecules; 2021 Feb; 26(4):. PubMed ID: 33578831 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]